BÜHLMANN IBDoc®

IBDoc Publications
ECCO 2021 - Compliance with Faecal calprotectin home testing as standard during COVID-19 pandemic compared to laboratory based testing pre-COVID
ECCO 2020 - IBDoc® Faecal calprotectin self-test retrospective audit in a District General Hospital (DGH)
ECCO 2020 - An evaluation of the impact of IBDoc® in clinical practice 5 years after introduction
ECCO 2019 - A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients
ECCO 2019 - Head-To-Head Comparison of Three Stool Calprotectin Tests for Home Use
ECCO 2018 - New faecal calprotectin cut-off points for remission and active disease defined by UCEIS and Nancy indices in ulcerative colitis (UC)
ECCO 2018 - Home based faecal calprotectin testing: a Canadian user performance evaluation study of IBDoc®

“FC measurements produced by patients with IBDoc were strongly correlated with the standard FC ELISA measurements. Patients found the IBDoc home kit easy to use and a product they would like to use in the future”

Moore. A et al ECCO 2018
ECCO 2018 - Patient’s performance and feedback by using home test faecal calprotectin as an objective reported outcome

“Correlation between the Quantum Blue test and the IBDoc results was good. Patients preferred to use the home test system for their disease monitoring”

Wei. S et al ECCO 2018
ECCO 2018 - IBDoc® self-care/point-of-care calprotectin test: Early value in a district general hospital inflammatory bowel disease service

“IBDoc adds value to patient care; it enhances the patient’s journey allowing quick treatment decisions to be made saving at least one hospital admission during this small trial”

Avery. P et al ECCO 2018
Usability of a home-based test for the measurement of fecal calprotectin in IBD patients

“Usability scores for the home-based test were high. There was a very good correlation with the centrally measured FC by ELISA”.

Bello. C et al Digestive and Liver Disease 2017
Home smart-phone based measurement of fecal calprotectin by IBD patients: correlation with laboratory assay and applicability as patient-friendly monitoring tool

“the results of the home fecal calprotectin test (IBDoc) correlate well with values-ranges obtained using conventional lab-based calprotectin test. Smart-phone based fecal calprotectin test may be a useful patient-friendly tool for monitoring of IBD patients at home, with minimal interference to their routine.”

Ungar. B et al ECCO 2017 P181
Home or hospital-based analysis of stool calprotectin: assessing two methods for monitoring inflammatory bowel disease

“80% of all paired measurements were concordant”

Heida. A et al. ECCO 2017 P374
An evaluation of patient satisfaction with IBDoc calprotectin home test system

“Calprotectin home testing using a smartphone as measuring system was very well received among the tested users (100% satisfaction). IBDoc offers patient empowerment for IBD patients who can remotely monitor their disease from the convenience of their own home”.

Fitzgerald. D et al. ECCO 2017 N804
Home testing for faecal calprotectin: follow-up results from the first UK trial

“A negative fCAL (<100μg/g) by either method is a useful test to exclude a flare within four months………….”

Raker. J et al ECCO 2017 P599
Cost effective of IBDoc as a surrogate marker of mucosal healing in IBD patients post induction of biological agents

“In total 53 clinical visits and 62 colonoscopies were saved….. this study demonstrate a significant cost effectiveness of using IBDoc faecal calprotectin post induction of anti-TNF therapy as well as reducing the waiting time for both clinic visits and colonoscopies”.

Elsafi. G et al UEGW 2017
Home-testing of faecal calprotectin using the IBDoc™ system: a comparative pilot study

‘’85% of respondents preferred the IBDoc test over other methods’’

Parr et al Poster at BSG 2016 PTH-054
Validation of a smartphone-based patient monitoring system measuring calprotectin as the therapy follow-up marker

“The performance of the smartphone-based IBDoc home testing system is comparable to professional, laboratory based methods”.

Weber et al Poster at UEGW 2015
Usability Study of a Smartphone-Based Calprotectin Home Test

This study shows that calprotectin home testing using a smartphone as measuring system was well accepted among IBD Patients. The complexity of the application is low, the entire IBDoc ® system can be considered very user-friendly and is easy to handle by lay users without prior knowledge or experience with stool extraction and immunochromatographic rapid tests.

Beyer et al United European Gastroenterology Week 2009
Usability study of a smartphone-based patient monitoring system measuring Calprotectin for therapy follow-up

This usability study shows that calprotectin home testing using a smartphone as measuring system was well accepted among the tested lay users. The complexity of the application is low, the entire IBDoc ® system can be considered very user-friendly and is easy to handle by lay users without prior knowledge or experience with immunochromatographic rapid tests.

Reinhard et al ECCO 2015
Homecare Systems for monitoring inflammatory bowel diseases are feasible and appreciated by both patients and healthcare professionals

The concept of patients participating in their own care is receiving widespread support. Homecare is an essential instrument since it both empowers patients and de-burdens healthcare professionals. Our results encourage us to proceed with homecare for IBD patients since the majority of patients are well motivated and able to complete periodic e-consulting.

van Helden et al Poster at UEGW 2009
Gastroenterology Today Spring 2023 - Calprotectin Home Testing - What do the Patients Think?

Results from a patient survey of IBDoc users at Basildon University Hospital show a high level of satisfaction, particularly from the benefits of getting an immediate calprotectin result and how that helps with disease management.

Read the Article
Point-of-care faecal calprotectin testing in patients with paediatric inflammatory bowel disease during the COVID-19 pandemic

Home calprotectin tests were useful in guiding clinical management during a time when laboratory testing was less available. They may offer benefits as part of routine paediatric IBD monitoring to help target appointments and reduce unnecessary hospital attendances in the future.

Jere, et al. (2021) BMJ Open Gastroenterology Volume 8, Issue 1
Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience

The IBDoc® is a simple tool to use and high satisfaction is found among IBDoc® users. IBD patients should be adequately informed and trained on the use of this test. FC home tests are an additional value for e-health approach in IBD patients. In the near future, these tests could allow not only tight monitoring of IBD patients but also their greater involvement in disease management.

D’Amico et al.  MDPI
Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring

The correlation between the laboratory and home tests was good. Most patients found the home test to be feasible and easy to use and preferred it over laboratory test and endoscopy for monitoring. Therefore, the home test could be used as an objective patient-reported outcome.

Wei et al.  Intestinal Research Journal
Big Changes Coming Soon to a Clinic Near You – Calprotectin Testing Goes Mobile

With the advances in technology and specifically the ubiquitous use of mobile devices developed during the last decade, a huge opportunity has arisen to change the way some healthcare services are provided. This is especially applicable to the management of chronic conditions. With most people owning a mobile device or tablet this becomes a convenient way for patients to communicate with their consultants for support and treatment advice.

Article in Gastroenterology Today Spring 2018
Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity

“We found sufficient agreement between the home used lateral flow test and the hospital based ELISA test in the lower ranges of calprotectin to use this new test for telemonitoring of patients with asymptomatic IBD” Uses BÜHLMANN fCAL® ELISA , Quantum Blue® fCAL and IBDoc®”

Heida. A et al. J of Gastroenterology and Hepatology 2017
Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis

“We found a strong correlation coefficient of 0.887 between FC measured on IBDoc® and the laboratory assay BÜHLMANN fCAL® turbo”.

Hejl. J et al 2017 Practical Laboratory Medicine
Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease